Patent intelligence · US
US 12269820
Piperazine substituted indazole compounds as inhibitors of PARG
Piperazine substituted indazole compounds as inhibitors of PARG
Patent details — US 12269820
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 8, 2025
- Expiration
- Apr 3, 2045
- Applicant
- IDEAYA Biosciences, Inc.
- Claims
- 12
- CPC classes
- A61P, A61P35/00
Quick answer
US 12269820 (Piperazine substituted indazole compounds as inhibitors of PARG) is held by IDEAYA Biosciences, Inc.. Status: granted. Granted Apr 8, 2025. Expires Apr 3, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- IDEAYA Biosciences, Inc.
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61P, A61P35/00
More from IDEAYA Biosciences, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12398131
Thiadiazolyl derivatives as DNA polymerase theta inhibitors and uses thereof
granted -
US 12258354
AhR modulators
granted -
US 12115163
Combination therapy comprising a MAT2A inhibitor and a type II PRMT inhibitor
granted -
US 11584755
Dihydrothieno[3,2-b]pyridine compounds
granted -
US 11548867
Amido compounds as AhR modulators
granted -
US 11530220
Substituted imidazo[1,5-a]pyrazines and [1,2,4]triazolo[4,3-a]pyrazines for the modulation of AhR
granted -
US 11407764
AhR modulators
granted
Frequently asked questions
What is US patent 12269820?
US 12269820 (Piperazine substituted indazole compounds as inhibitors of PARG) is held by IDEAYA Biosciences, Inc.. Status: granted. Granted Apr 8, 2025. Expires Apr 3, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12269820?
IDEAYA Biosciences, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 12 pharmaceutical patents for this assignee.
When does US 12269820 expire?
Our index shows an expiration date of Apr 3, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.